# Ratio-Driven Lipoprotein Mapping Refines Genetic Pathways of Cardiometabolic Risk

**Authors:** Karsten Suhre, Murugan Subramanian, Melanie Modder, Abulaish Anasari, Haiyue He, Christopher Krumm, Farooq Rashid, Raghad Al-Ishaq, Aziz Belkadi, Tanwir Habib, Anna Halama, Nisha Stephan, Gaurav Thareja, Shaza Zaghlool, Audrey D Dujardin, Xi Chen, Peter Mulligan, Eric B. Fauman, Ann-Hwee Lee, Patrick C. N. Rensen, Sander Kooijman, David E Cohen, S. Hani Najafi-Shoushtari

PMC · DOI: 10.21203/rs.3.rs-8475327/v1 · Research Square · 2026-01-07

## TL;DR

This study uses lipoprotein ratios to uncover new genetic pathways and mechanisms involved in cardiovascular risk and lipid metabolism.

## Contribution

The study introduces a novel ratio-driven approach to fine-map lipid risk loci and identifies new biomarkers and mechanisms for drug target development.

## Key findings

- New ratio-based markers like linoleic acid fraction and LDL cholesterol esterification were identified as proxies for lipid metabolism pathways.
- miR-148a was found to be a previously unrecognized determinant of Lp(a) levels, linking ER-stress and VLDL metabolism.
- HDL fraction of total lipoprotein particle number was identified as a predictor of myocardial infarction.

## Abstract

Dysregulated blood lipids are a major predictor of cardiovascular events. A recent genome-wide association study (GWAS) with five clinically relevant lipid traits in 1.65 million individuals implicated over 770 genomic regions in regulating blood lipid metabolism. To translate these associations into clinical applications, a functional understanding of their roles in lipoprotein metabolism, transport and remodeling (LPmtr) is required. Here, we report the deep molecular fine-mapping of 554 of these lipid risk loci using 168 lipoprotein-related traits and all possible ratios between them in over 273,000 participants of the UK Biobank. We identified new ratio-based markers of pathways shared by multiple LPmtr genes, such as the linoleic acid fraction of the polyunsaturated fatty acid pool to reveal potential causal genes at poorly characterized lipid risk loci, the percentage of esterified cholesterol moieties in LDL particles as a proxy for soluble LDL receptor levels, and the HDL fraction of total lipoprotein particle number as a predictor of incident myocardial infarction. We demonstrate how lipoprotein fine-mapping can generate new hypotheses for drug target development while uncovering new mechanisms relevant to hyperlipidemia. Ratio-driven clustering further implicated miR-148 in TG secretion, linking ER-stress responses at postprandial state to VLDL metabolism via mTORC1, shown through series of integrated cellular assays and mouse studies. Moreover, consistent with its regulatory influence on lipid flux we identify miR-148a a previously unrecognized determinat of Lp(a) levels. Our study implements a novel approach of using metabolomic data to follow-up on genetic evidence from GWAS with clinical traits and generates new insights into the biology of lipoprotein particles, supporting the emerging view that assessing lipoprotein size and composition is essential for the understanding, prevention, and treatment of lipid-related disorders.

## Linked entities

- **Genes:** MIR148A (microRNA 148a) [NCBI Gene 406940]
- **Chemicals:** linoleic acid (PubChem CID 5280450), Lp(a) (PubChem CID 5497152)
- **Diseases:** hyperlipidemia (MONDO:0021187), myocardial infarction (MONDO:0005068)

## Full-text entities

- **Genes:** Lpl (lipoprotein lipase) [NCBI Gene 16956], Hsp86-ps2 (heat shock protein 86, pseudogene 2) [NCBI Gene 111042] {aka 86kDa, Hsp86-3, Hsp90}, Ddit3 (DNA-damage inducible transcript 3) [NCBI Gene 13198] {aka AltDDIT3, CHOP-10, CHOP10, chop, gadd153}, Apob (apolipoprotein B) [NCBI Gene 238055] {aka Apo B-100, apob-100, apob-48}, Fasn (fatty acid synthase) [NCBI Gene 14104] {aka A630082H08Rik, FAS}, Adrb1 (adrenergic receptor, beta 1) [NCBI Gene 11554] {aka Adrb-1, beta-AR}, Tsc2 (TSC complex subunit 2) [NCBI Gene 22084] {aka Nafld, Tcs2}, Copz2 (coatomer protein complex, subunit zeta 2) [NCBI Gene 56358] {aka 1110012D12Rik, zeta2-COP}, Ldlr (low density lipoprotein receptor) [NCBI Gene 16835] {aka Hlb301}, XBP1 (X-box binding protein 1) [NCBI Gene 7494] {aka TREB-5, TREB5, XBP-1, XBP2}, Fads2 (fatty acid desaturase 2) [NCBI Gene 56473] {aka 2900042M13Rik, Fads2a, Fadsd2}, ATF6 (activating transcription factor 6) [NCBI Gene 22926] {aka ACHM7, ATF6A, ATP6alpha}, MIR148A (microRNA 148a) [NCBI Gene 406940] {aka MIRN148, MIRN148A, hsa-mir-148, mir-148a}, LPA (lipoprotein(a)) [NCBI Gene 4018] {aka AK38, APOA, LP}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, ATF4 (activating transcription factor 4) [NCBI Gene 468] {aka CREB-2, CREB2, TAXREB67, TXREB}, Mogat2 (monoacylglycerol O-acyltransferase 2) [NCBI Gene 233549] {aka DGAT2L5, MGAT2, Mgat1l}, Apoa1 (apolipoprotein A-I) [NCBI Gene 11806] {aka Alp-1, Apoa-1, Brp-14, Ltw-1, Lvtw-1, Sep-1}, Ntan1 (N-terminal Asn amidase) [NCBI Gene 18203] {aka PNAA, PNAD}, Plch2 (phospholipase C, eta 2) [NCBI Gene 269615] {aka A930027K05Rik, PLCeta2, Plc-eta2, Plcl4}, Tert (telomerase reverse transcriptase) [NCBI Gene 21752] {aka EST2, TCS1, TP2, TR, TRT}, Elovl3 (ELOVL fatty acid elongase 3) [NCBI Gene 12686] {aka CIN-2, Cig30}, Angptl4 (angiopoietin-like 4) [NCBI Gene 57875] {aka Arp4, Bk89, Fiaf, Hfarp, Ng27, Pgar}, Pltp (phospholipid transfer protein) [NCBI Gene 18830] {aka Bpife, OD107}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Acot11 (acyl-CoA thioesterase 11) [NCBI Gene 329910] {aka 1110020M10Rik, 2010309H15Rik, BFIT, BFIT1, Thea, Them1}, Pla2g10 (phospholipase A2, group X) [NCBI Gene 26565] {aka GX sPLA2, PLA2GX, sPLA2-X}, Atf6 (activating transcription factor 6) [NCBI Gene 226641] {aka 9130025P16Rik, 9630036G24, Atf6alpha, ESTM49}, LCAT (lecithin-cholesterol acyltransferase) [NCBI Gene 3931], Npc1l1 (NPC1 like intracellular cholesterol transporter 1) [NCBI Gene 237636] {aka 9130221N23Rik, Gm243}, Ern1 (endoplasmic reticulum to nucleus signalling 1) [NCBI Gene 78943] {aka 9030414B18Rik, Ire1a, Ire1alpha, Ire1p}, ANGPTL4 (angiopoietin like 4) [NCBI Gene 51129] {aka ARP4, FIAF, HARP, HFARP, NL2, PGAR}, Tbc1d7 (TBC1 domain family, member 7) [NCBI Gene 67046] {aka 2610009C09Rik}, Apoh (apolipoprotein H) [NCBI Gene 11818] {aka B2GPI, beta-2-GPI, beta2-GPI}, Ern2 (endoplasmic reticulum to nucleus signalling 2) [NCBI Gene 26918] {aka Ern1, Ire1, Ire1b, ire1-beta, mIre1}, Alb (albumin) [NCBI Gene 11657] {aka Alb-1, Alb1, BCL001, BCL002, BPL001}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, Hspa5 (heat shock protein family A (Hsp70) member 5) [NCBI Gene 14828] {aka Bip, D2Wsu141e, D2Wsu17e, Grp78, Hsce70, SEZ-7}, Abca6 (ATP-binding cassette, sub-family A member 6) [NCBI Gene 76184] {aka 6330565N06Rik}, Pdxdc1 (pyridoxal-dependent decarboxylase domain containing 1) [NCBI Gene 94184] {aka 2210010A19Rik, Kiaa0251-hp}, Tsc22d1 (TSC22 domain family, member 1) [NCBI Gene 21807] {aka Egr5, Gm19597, TSC-22, Tgfb1i4, Tsc, Tsc22}, Pparg (peroxisome proliferator activated receptor gamma) [NCBI Gene 19016] {aka Nr1c3, PPAR-gamma, PPAR-gamma2, PPARgamma, PPARgamma2}, PLG (plasminogen) [NCBI Gene 5340] {aka HAE4}, Mlxipl (MLX interacting protein-like) [NCBI Gene 58805] {aka ChREBP, Mlx, WS-bHLH, Wbscr14, bHLHd14}, Pemt (phosphatidylethanolamine N-methyltransferase) [NCBI Gene 18618] {aka PEAMT, PEMT2, PLMT, Pempt, Pempt2}, Eif4ebp1 (eukaryotic translation initiation factor 4E binding protein 1) [NCBI Gene 13685] {aka 4e-bp1, PHAS-I}, SCD (stearoyl-CoA desaturase) [NCBI Gene 6319] {aka FADS5, MSTP008, SCD1, SCDOS, hSCD1}, TSC2 (TSC complex subunit 2) [NCBI Gene 7249] {aka LAM, PPP1R160, TSC4}, Pcsk9 (proprotein convertase subtilisin/kexin type 9) [NCBI Gene 100102] {aka FH3, HCHOLA3, Narc1, PC9}, Dgat1 (diacylglycerol O-acyltransferase 1) [NCBI Gene 13350] {aka ARAT, D15Ertd23e, Dgat}, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) [NCBI Gene 3156] {aka LDLCQ3, LGMDR28, MYPLG}, Copz1 (coatomer protein complex, subunit zeta 1) [NCBI Gene 56447] {aka 5930435A22Rik, D4Ertd360e}, FASN (fatty acid synthase) [NCBI Gene 2194] {aka FAS, OA-519, SDR27X1}, Tsc1 (TSC complex subunit 1) [NCBI Gene 64930], Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Rrn3 (RRN3 RNA polymerase I transcription factor homolog (yeast)) [NCBI Gene 106298] {aka E130302O19Rik, TIF-1A, Tif1a}, Srebf1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 20787] {aka ADD1, SREBP1, bHLHd1}, Eif2s2 (eukaryotic translation initiation factor 2 subunit 2 beta) [NCBI Gene 67204] {aka 2810026E11Rik, 38kDa, D2Ertd303e, EIF2, EIF2B}, Dgat2 (diacylglycerol O-acyltransferase 2) [NCBI Gene 67800] {aka 0610010B06Rik, ARAT, DGAT-2}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}
- **Diseases:** lipid-related disorders (MESH:D011017), hepatoma (MESH:D006528), NMR (MESH:C564596), obesity (MESH:D009765), hyperlipidemia (MESH:D006949), myocardial infarction (MESH:D009203), TC (MESH:C535937), breast cancer (MESH:D001943), hepatic steatosis (MESH:D005234), cardio-metabolic disease (MESH:D008659), inflammation (MESH:D007249), ER-dysfunction (MESH:D008228), NAFLD (MESH:D065626), ASCVD (MESH:D050197), Hepatic carsinoma (MESH:D056486)
- **Chemicals:** creatinine (MESH:D003404), LA (MESH:D019787), DMEM (-), 2-propanol (MESH:D019840), SMs (MESH:D013109), glutamine (MESH:D005973), Midazolam (MESH:D008874), glycine (MESH:D005998), citrate (MESH:D019343), MUFAs (MESH:D005229), lactate (MESH:D019344), glitazones (MESH:D045162), omega-3 fatty acids (MESH:D015525), omega-6 fatty acids (MESH:D043371), cholines (MESH:D002794), valine (MESH:D014633), TM (MESH:D014415), LP(a) (MESH:D010649), 3-hydroxybutyrate (MESH:D020155), lipid (MESH:D008055), Trizol (MESH:C411644), fatty acid (MESH:D005227), 35S (MESH:C000615320), Fentanyl (MESH:D005283), CE (MESH:D002788), Rapamycin (MESH:D020123), PE (MESH:C483858), cocoa butter (MESH:C052387), FC (MESH:C095424), amino acids (MESH:D000596), glucose (MESH:D005947), leucine (MESH:D007930), Brefeldin A (MESH:D020126), pyruvate (MESH:D019289), PM (MESH:D010168), ezetimibe (MESH:D000069438), Cholesterol (MESH:D002784), phosphoglycerides (MESH:D020404), Lipofectamine (MESH:C086724), corn oil (MESH:D003314), CO2 (MESH:D002245), PL (MESH:D010743), water (MESH:D014867), histidine (MESH:D006639), ketone bodies (MESH:D007657), acyl-CoA (MESH:D000214), TG (MESH:D014280), alanine (MESH:D000409), SYBR green (MESH:C098022), streptomycin (MESH:D013307), gamma-linolenic acid (MESH:D017965), acetone (MESH:D000096), DMSO (MESH:D004121), PUFA (MESH:D005231), docosahexaenoic acid (MESH:D004281), isoleucine (MESH:D007532), acetoacetate (MESH:C016635), penicillin (MESH:D010406), acetate (MESH:D000085), PC (MESH:D010713)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** rs267738, rs174564, rs2297359, rs328, rs12928099, rs11843064, rs77542162, rs4722551, rs676210, rs12916, rs1065853, rs9296406, rs448092, rs72997616, rs2003892, rs4986970, rs673335, rs267733, rs7924036, rs3747207, rs10199768, rs138905573, rs10896373, rs10455872, rs368178, rs1123571, rs10779835
- **Cell lines:** Huh7 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_0336), C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), T47D — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0553), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12803353/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12803353/full.md

## References

70 references — full list in the complete paper: https://tomesphere.com/paper/PMC12803353/full.md

---
Source: https://tomesphere.com/paper/PMC12803353